Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Prestige Consumer Healthcare Inc.
PBH
NYSE·Healthcare·Medical - Distribution·Mkt cap $2.3B
$49.24
▲ +2.24%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$42.62 - $80.69
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 39.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Established brand portfolio with high consumer recognition and loyalty
- Efficient multi-channel distribution network across retail, pharmacy, and e-commerce
- Proven acquisition and operational optimization capabilities for underperforming brands
- Diversified product range across multiple therapeutic categories reducing category-specific risk
- Strong cash generation and low capital intensity enabling shareholder returns
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
E-commerce expansion and direct-to-consumer channel growth
Value
Undervalued - trading well below Healthcare Distribution peers
Momentum
Weak
-8.2% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PBH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 13, 2026
Reported EPS of $1.23 vs $1.39 consensus (-11.5% surprise). Revenue of $281.6M vs $293.6M expected (-4.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-11.5%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
—
+3%
+7%
-7%
-3%
-2%
Q4 24
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
$277.0M
$267.1M
$283.5M
$290.3M
$296.8M
$249.5M
$274.1M
$283.4M
Margins · last 8Q
Gross
55.5%
Operating
29.1%
Profit
16.5%
Wall Street consensus
3 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
—
Latest: Canaccord · May 15, 2026